Switzerland-based Regen Lab has received CE certification for three medical devices, namely REGENKIT, CELLULAR MATRIX fig and Arthrovisc.

REGENKIT is a preparation of platelet-rich plasma (PRP) while CELLULAR MATRIX fig is a combination of PRP and hyaluronic acid (HA). Arthrovisc comprises syringes filled with HA.

The PRP solutions received the certificates from the notified body BSI based on the evaluation of Regen Lab’s quality management system and technical documentation.

The validity period of these certificates spans five years, commencing on 25 April 2023 and concluding on 24 April 2028.

Regen Lab’s certifications strengthen its competitive position both in the PRP market and when combined with HA.

The CE certification obtained for the devices under Medical Device Regulation bolsters the company’s positioning in the field of autologous tissue engineering therapies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Regen Lab’s autologous tissue engineering solutions are based on PRP preparation from the patient’s own blood and combined therapy that includes PRP and HA.

The certification also highlights the company’s patented technologies, which are available in more than 90 countries.

These technologies were used to treat patients in musculoskeletal, dermo-esthetics, wound care and urogenital therapeutic areas.

The commercial-stage medical technology company is engaged in the development, registration, manufacturing and commercialisation of tissue engineering solutions.

Its products are produced at the group facilities in Le Mont sur Lausanne, Switzerland, and Brooklyn, New York, US.

The company will also start manufacturing operations in Les Ulis, Paris, France, in the third quarter of this year.